Advocacy Archives

Turning Adversity Into Action | Patient Summit Seminar on Advocacy for RKD

Click to Watch…

During the 2024 Patient Summit, we were joined by 250+ patients and families who were able to gain knowledge and support surrounding their rare kidney disease and how to maintain their health.

Britta Dornan, NephCure’s Executive Director of Strategic Relations, hosted a panel with Texas Senator Kelly Hancock, Mary Baliker, Lisa Cimino, and Kimberly Queen surrounding their journey with RKD and how to turn their adversity from their disease into actionable cause.

Visit our Youtube page

Share this

Kidney Health Advocates from Across the Country Urge Congress to Support the New Era Act During NephCure’s Rare Kidney Day at the U.S. Capitol

NephCure mobilized nearly 70 patients, advocates, and medical professionals to advocate for federal legislation to improve the understanding and treatment of rare kidney diseases.

Washington, DC, August 8, 2024 – NephCure, the only national kidney organization squarely focused on rare, protein-spilling kidney diseases, hosted its annual Rare Kidneys on the Hill Day in late July to advocate for the New Era of Preventing End-Stage Kidney Disease Act (H.R. 6790), bipartisan federal legislation to improve the lives of rare kidney disease patients. The annual Hill Day included nearly 90 in-person meetings with members of Congress and legislative staff followed by an evening reception for congressional staff, patients, and their families. Sixty-eight advocates, including six physician advocates, from 22 states traveled to Washington, D.C. to participate in the annual event. As a direct result of Hill Day, an additional eight members of Congress across political parties signed on to co-sponsor the New Era Act, bringing the total number of cosponsors to 14.

NephCure advocates and staff conducted nearly 90 in-person meetings with congressional staff from the U.S. Senate and House of Representatives, more than they had ever held at a Rare Kidneys on the Hill Day before. Advocates met with staff from Congressional offices including Representatives Jefferson Van Drew (R-NJ), Susan Wild (D-PA), Michael Lawler (R-NY), Glenn Thompson (R-PA), Bill Pascrell (D-NJ), and Bill Posey (R-FL).

“The New Era Act gives hope to the kidney disease community, offering a comprehensive approach to early detection, provider education, and innovative treatments that will enhance the quality of life for patients and their families,” said Matthew Johnson, Director, Government Relations and Advocacy at NephCure. “We are incredibly grateful to the dedicated advocates who participated in this Hill Day to urge Congress to pass the New Era Act to help usher in a new era of kidney health. It’s the courage and commitment of patients living with rare kidney diseases, their families, and the physicians who care for them that are the driving force behind NephCure.”

Introduced by Representatives Gus Bilirakis (R-FL) and Terri Sewell (D-AL), the New Era Act is bipartisan legislation aimed at transforming the way our nation approaches kidney health through early detection, research, and innovative treatments to combat kidney disease. The New Era Act seeks to expand access to screening and educational resources, invest in cutting-edge research, and enhance care coordination for patients with kidney disease. By prioritizing diagnosis and innovation, the New Era Act holds the promise of improving the lives of millions of Americans at risk of or living with kidney disease, while also reducing associated healthcare costs.

You can watch a video of Rare Kidneys on the Hill Day her e.

About NephCure

NephCure is the only kidney organization focused on nephrotic syndrome, FSGS, IgAN, and other rare, protein-spilling kidney diseases. They are working on creating a new reality where more rare kidney disease (RKD) therapies exist, and more patients get the care they need.

To date, NephCure has invested $40 million into rare kidney disease research, growing the number of interventional drug trials for RKD from zero to more than sixty and counting. Everything Nephcure does is for RKD patients, connecting them and their families to the best care, resources, and community support available. NephCure collaborates directly with government officials and industry partners to pave the way for more clinical trials, drug approvals, and community awareness. By building bridges between patients, families, healthcare providers, and other key stakeholders, they lift everyone up under one common purpose: to find a cure for rare kidney disease.

About the New Era Act

The New Era of Preventing End-Stage Kidney Disease Act (“New Era Act”), introduced by Representatives Gus Bilirakis (R-FL) and Terri Sewell (D-AL), has the potential to bring about significant positive changes in how we understand, treat, and study rare kidney diseases (RKD).

Empower Patients & Communities. The New Era Act will support public information and patient education campaigns, promoting informed communities and empowering patients to take charge of their health care journey.

Share this

NephCure Launches Advocacy Academy to Empower Rare Kidney Disease Advocates

Philadelphia, PA — May 1, 2025 — NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare, protein-spilling kidney diseases, is proud to announce the launch of its inaugural Advocacy Academy, a four-week program designed to build and strengthen the advocacy skills of rare kidney disease (RKD) patients, families, and allies.

Beginning today, Advocacy Academy participants will embark on a focused journey to become more effective champions for the RKD community. The course will offer targeted training on critical advocacy skills, including legislative engagement, storytelling for impact, and grassroots mobilization.

Graduates of the Advocacy Academy will be fully prepared to participate in Rare Kidneys on the Hill Day on July 23-24, 2025, where they will meet directly with elected officials to advocate for vital policies such as the New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518) and other initiatives supporting RKD patients. Participants will also be empowered to lead advocacy efforts in their own state and local communities year-round.

“Our goal is to equip our advocates with the tools they need to create real change,” said Matthew Johnson, NephCure Director of Government Relations and Advocacy. “By investing in their development, we are strengthening the voice of the RKD community and ensuring policymakers hear directly from those most impacted.”

Throughout the course, participants will engage in interactive sessions, complete quick educational modules via NephCure’s Advocacy Accelerator platform, and work toward a final advocacy project to cap off their training.

NephCure’s Advocacy Academy efforts would not be possible without the generous support of its sponsors, Travere Therapeutics, Novartis, and Otsuka.

For more information about NephCure’s Advocacy Academy or to get involved in rare kidney disease advocacy, please click here or contact advocacy@nephcure.org.

About NephCure

NephCure’s mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity.

Share this

2015 Countdown to a Cure – THANK YOU!

We’ve said “hello” and “goodbye” to another Countdown to a Cure…

From the beautiful scenery of New York City’s Chelsea Piers, to the heartfelt speeches delivered by NephCure’s beloved family, the Jones’ and honoree, Olympic athlete Aries Merritt, this event was truly the “Chance of a Lifetime” to make a difference in the fight against Nephrotic Syndrome. The success of Countdown has always been measured by the generosity of the many hundreds in attendance who consistently show support for NephCure and this year, our expectations were overwhelmingly exceeded, for which we could not be more grateful. You are changing the story.

Energies were high and attendees were excited, lighting the way for one of the most successful galas in NephCure history. “Fund a Cure” donations blew expectations out of the water, bidding was at a high and the second annual game of “heads or tails,” brought a touch of silliness to an evening surrounding a very serious cause. Emcee, Moody McCarthy, along with “Asbury Fever,” a Bruce Springsteen Tribute band, kept the party going all night long with many moments filled with laughter, dancing and mingling.

As always, we want to thank the committee who worked so hard to put this event together and the volunteers who generously gave up their time to help this event flourish into a huge success. The 2015 New York Countdown to a Cure raised over $750,000 and many left the event feeling inspired and hopeful.

Finally, thanks to YOU. To each of you reading this who’ve decided to join us in this fight.

We can’t do this alone.
We need you, we’re grateful for you and we thank you.

Share this

NephCure Launches National Coalition to Advocate for Policy Solutions that Revolutionize Rare Kidney Disease Care & Improve Patient Outcomes

We deserve better - New Era Act in Rare Kidney Disease Care - Advocacy

Philadelphia, PA, June 12, 2024 – NephCure, a leading national patient advocacy organization dedicated to accelerating research and finding better treatments for rare kidney diseases, today announced the launch of the New Era Coalition, a first-of-its-kind initiative uniting diverse communities to transform the landscape of research, treatment, and care for rare kidney diseases (RKD). The New Era Coalition brings together patient advocacy groups, medical experts, academic leaders, industry, and other key stakeholders to advance policy and regulatory solutions that move kidney care upstream. The New Era Coalition will advocate for federal and state policies that work to improve outcomes for RKD patients, including the New Era of Preventing End-Stage Kidney Disease Act, H.R. 6790 (“New Era Act”).

“We are proud to spearhead the formation of the New Era Coalition and unite communities to revolutionize rare kidney disease care, improve patient outcomes, and pave the way for a better future for those affected by these diseases,” said Britta Dornan, NephCure Executive Director of Strategic Relations. “For too long, rare kidney disease patients and caregivers have felt powerless and alone, but together we can effect real change. The time has come for policymakers in Washington and states to listen and take decisive action to improve treatment and care for rare kidney disease communities, including by passing the New Era Act this year.”

More than a dozen influential organizations and patient advocates have joined as New Era Coalition inaugural members to champion policy and advocacy solutions for the RKD community. Alongside NephCure, New Era Coalition members include patient advocates Mary Baliker, Seferiana Day, and Imani Mintz and organizations including the Alport Syndrome Foundation, American Kidney Fund, American Society of Nephrology, Black Women’s Health Imperative, Chronic Disease Coalition, IgA Nephropathy Foundation, International Society of Glomerular Disease, National Kidney Foundation, National Minority Quality Forum, Northwest Kidney Council, and the Rare Disease Diversity Coalition. New Era Coalition advisory members include Arkana Laboratories, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical Inc., Travere Therapeutics, and Vertex Pharmaceuticals.

During the 118^th Congress, the New Era Coalition will pursue robust efforts to ensure the passage of the New Era Act. Introduced by Representatives Gus Bilirakis (R-FL) and Terri Sewell (D-AL), the New Era Act stems from the community insights gained in 2020 by NephCure and partner organizations from the ‘We Deserve Better: Revolutionizing Rare Kidney Disease Roundtable’ and its resulting white paper.This legislation aims to help people with RKD by finding and treating diseases earlier, enhancing patient and provider education, and conducting more research. The New Era Act would lessen the impact of RKD on people’s lives and reduce costs for patients and the health care system in the long run.

About the New Era Coalition

The New Era Coalition brings together patient advocacy groups, medical experts, academic leaders, industry, and other key stakeholders, to transform the landscape of research, treatment, and care for rare kidney diseases (RKD).

About NephCure

Share this

NEW Funding Source for FSGS

President Obama signed the appropriations package to fund federal agencies through fiscal year 2015 (ending September 30, 2015). This includes allocations for NIH and other health care funding agencies such as the Department of Defense (DoD), which oversees the Peer-Reviewed Medical Research Program (PRMRP).

For the first time, FSGS is listed as a condition eligible to study in the PRMRP. Because FSGS is listed, FSGS researchers have an opportunity to compete for grants from a NEW funding source. This is HUGE. This opportunity is a direct result of NephCure’s professional and volunteer advocacy work in Washington, D.C. and the efforts of our staff to work collaboratively with scientific partners at NIH and the VA to highlight the benefits of studying this disease through the DoD program. The total amount in the PRMRP program is $247.5 MILLION!

UPDATE:

The Program Announcement was released April 17 for the 2015 cycle. There are five funding mechanisms available. Click here for details.

Share this

2014 Research In Review

What a Year We Had in 2014!

Thank you to all those who collaborate with NephCure Kidney International (NKI) to advance its mission to support research leading to better treatments and cures for those suffering with FSGS and other Nephrotic Syndrome diseases. 2014 saw several major successes in the research world that move us closer to achieving our goals.

Below is a summary of NKI’s 2014 research-related accomplishments.

NEPHCURE KIDNEY NETWORK PATIENT REGISTRY

Hundreds of people with primary FSGS and related glomerular diseases enrolled in the newly launched NephCure Kidney Network Patient Registry. These patients and care givers of patients are at the forefront of a movement called “patient powered research”. By sharing and comparing data contributed by patients about their health and quality of life, we can accelerate the development of new treatments, including new drugs. It is important for people with a rare disease to STAND UP & BE COUNTED to ensure research focuses on the issues of greatest importance to patients and their families. To learn more or enroll, click HERE.

RESEARCH GRANTS

In 2014, the NKI grant program committed over $2.6 MM in support for scientific investigations that advance knowledge about the cause of NS disease, evaluate possible drug targets and help physician/scientists track the natural history of these rare diseases. Click HERE for more information about grants awarded to investigators at Washington University Medical Center, Boston Children’s Hospital and Rush University. For more information about the research consortia we support, click HERE for the Nephrotic Syndrome Study Network and HERE to learn more about CureGN.

CLINICAL TRIALS

Patient participation in clinical research is essential to advance new treatments. In 2014, NKI launched several new programs to educate patients and increase awareness of opportunities to participate in research.

The NEW Clinical Trial Finder website lists 16 studies actively recruiting participants in the US and Canada and another 18 around the world.
We launched a Clinical Trial Ambassadors Program to recruit and train volunteers to help educate patients about the benefits (and risks) to participate in clinical trials and educate the medical community about the need for more research into treatments for NS.
We posted, tweeted, emailed and sent letters about NEW FSGS drug trials. Our activities have raised awareness for potential participants and increased the interest of biopharmaceutical companies in working with NKI to advance new drug trials.

CATALYZE, COLLABORATE AND CONVENE

NKI is dedicated to being a catalyst along the research continuum: from support for basic science research to working with the biopharmaceutical industry and the FDA to understand how we might increase the numbers of new drugs moving into the drug approval pipeline and, finally, how to rapidly integrate new treatments into health care practice.

2014 was a busy year as we joined forces with our partners in healthcare and research to promote better treatments and faster cures.

The advocacy work of NKI volunteers, staff and our professional partners in Washington, D.C. was instrumental in significant NEW FUNDING for FSGS and NS research in 2014.

The National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health (NIH) awarded $10 MM in new funding to continue the Nephrotic Syndrome Study Network (NEPTUNE), a consortium of research centers in the US and Canada collecting and analyzing data about patients newly diagnosed with primary NS diseases. NKI was a principal funder of the first phase of this study and continues to support and participate in its expansion.
A second institute in NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a new $20 MM, 5- year grant to follow patients with FSGS, Minimal Change Disease, Membranous Nephropathy and IgA Nephropathy. NKI was instrumental in collaborating with NIH to get this funding. Click HERE.
For the first time, FSGS is listed as a condition eligible to receive research grants through the Department of Defenses’ Peer-Reviewed Medical Research Program. Because FSGS is listed, FSGS researchers have an opportunity to compete for grants from a NEW funding source. The total amount in the DoD’s program is $247.5 Million!

NKI is a leader in assembling, facilitating and promoting professional meetings that bring together partners from industry and the academic world along with patients and their advocates to promote NS health research. In 2014, NKI:

Organized the 10^th International Podocyte Conference in Freiburg, Germany. This conference brings together researchers from a variety of scientific disciplines and from around the world to promote interactions and new collaborations and to investigate emerging directions in podocyte and glomerular biology research.
Convened the PRO in Glomerular Disease Scientific Conference with representatives from academic medical centers, the biopharmaceutical industry, the NIH and the FDA to pursue the development of Patient Reporting Outcome (PRO) instruments to advance new drug trials for FSGS and NS. (A PRO is any report of the status of a patient’s health condition that comes directly from the patient.) An FDA-accepted PRO instrument can accelerate the number of applications to the FDA for new drug trials. NKI continues to lead the development of a PRO development consortium.
Convened the third NephCure Research Accelerator Meeting that brought together physicians and scientists with representatives from more than a half dozen biopharmaceutical companies with an interest in drug development for kidney disease. Research Accelerator Meetings were initiated by NephCure to engage these two scientific groups in an exchange of knowledge that will accelerate translation of basic science discoveries to new treatments for people with NS diseases.
Presented a session on the NephCure Kidney Network and patient-powered research to the US Summit of Kidney Organizations hosted by the America Society of Nephrologists at its 2014 conference in Philadelphia. NKI continues to be a leader in bringing the voice of patients to the forefront of advocacy for new treatments for chronic kidney diseases such as FSGS, Minimal Change Disease and Membranous Nephropathy.

Share this

NephCure Kidney International and Local NY Teenager Sydney Levine Launch MARCHing to Awareness

FOR IMMEDIATE RELEASE

Contact Information:
NephCure Kidney International
Erin Russell
erussell@nephcure.org

NephCure Kidney International and Local NY Teenager
Sydney Levine Launch MARCHing to Awareness

{Melville, NY, March 2, 2016} – NephCure Kidney International and Sydney Levine, from Melville , NY, will be MARCHing to Awareness for the month of March. Sydney, 15, rang the closing bell at the NYSE yesterday to kick off her month long drive to promnote awareness of chronic kidney disease. Sydney’s brother, Matthew, 12, has Focal segmental glomerulosclerosis (FSGS), a rare kidney disease for which there is no cure.

MARCHing to Awareness is a campaign aimed at promoting f National Kidney Disease Awareness Month and will target a different activity each day of the month. Yesterday, March 1, Sydney spoke in front of the Suffolk County Legislature and rang the NYSE closing bell.

“Academics aside, I wanted to express my admiration for Matthew in the way he conducts himself. In spite of his condition, his positive attitude never waivers. I cannot remember the last time I didn’t see him with a smile on his face. Many kids would use his condition as a crutch or an excuse; he appears to use it as a motivator. I, for one, am inspired by this. I hope this month is just a start to finding a permanent solution to what Matthew and other kids like him are going through,” Chris Regini, Matthew and Sydney’s science teacher.

For more information, please visit www.nephcure.org or search #KidneyAwarenessMonth

NephCure Kidney International is the only organization committed exclusively to support research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and the diseases that cause Nephrotic Syndrome, improve treatment, and find a cure.

###

[Best_Wordpress_Gallery id=”10″ gal_title=”#KidneyMonthAwareness”]

Share this

Be Your Own Best Advocate

Hi, my name is Amanda, I’m an attorney, live in Chicago, and I have FSGS. When I was 26 I began gaining weight unexpectedly and a kidney biopsy a couple weeks later confirmed the diagnosis. Immediately I began steroid treatments, and responded well; however when we attempted to wean off the steroids, the symptoms returned.

After another failed round of steroids, I temporarily lost my health insurance and was unable to see a doctor. Fortunately, I was able to eventually obtain insurance and then was quickly admitted to the hospital because the swelling was so extreme. I’ve been on Cyclosporine, Cellcept and now started Prograff and fortunately my kidney function has remained stable.

Throughout my treatments, NephCure has been an important resource for me, grateful for the opportunity to interact with other patients and to talk to experts in the field.

My friends & family think I am fierce – I won’t let anything stand in my way. Some people assume that a rare disease diagnosis would stop your life in its tracks. But I’ve learned that things that would have caused anger or provoked frustration in the past seem unimportant now. Life is way too short to spend fighting or being upset about the little things. My husband Al and I now spend time advocating, fundraising, and working tirelessly with NephCure to help fund the cure for FSGS. We know what we want and what we all want is a cure!

We need more, we want more, and we want to give more. Won’t you join us in this fight?

Sincerely, Amanda

Share this

NephCure on Capitol Hill for 2014 Kidney Community Advocacy Day

May 12, 2014

On May 1, 2014 more than 100 advocates met with 133 congressional offices, including with 19 Senators and Representatives to raise the profile of kidney disease and make the case for investing in kidney research. Another goal was to garner additional co-sponsors for the Immunosuppressive Drug Coverage Act, which will extend coverage of immunosuppressive drugs for Medicare patients who receive a kidney transplant.

L-R NephCure Advocate Pam Duquette; NephCure CEO Henry Brehm; NephCure Advocate and FSGS Patient Melanie Stewart; Former NFL Player, Kidney Transplant Recipient and Friend of NephCure Donald Jones

Organized by the American Society of Nephrology (ASN), the advocacy day drew constituents from fourteen organizations, including NephCure Kidney International, lent support to the effort, joining forces to champion the cause of kidney disease research and treatment, which we hope will lead to a cure.

NephCure was also honored to have one of our own, Melanie Stewart, present to nearly 100 people at a congressional briefing on kidney research and innovation. The briefing, titled “Innovations in Kidney Disease Research: New Hope for Patients,” was co-chaired by U.S. Representatives Tom Marino (R-PA) and Jim McDermott (D-WA), both of whom spoke about their strong support for the kidney community and for research funding to develop cures. “It’s a privilege to tell my story and raise awareness of FSGS, and possible transplant challenges for kidney disease patients,” Stewart said.

About The NephCure Foundation
NephCure Kidney International is the only organization solely committed to seeking a cause and cure for Nephrotic Syndrome and Focal Segmental Glomerulosclerosis (FSGS). Comprised of patients, their families and friends, researchers, physicians and other healthcare professionals, NephCure aims to help science unlock the biological mechanisms that cause these serious conditions and ultimately find a way to cure and prevent them.

Additional Information About The Legislative Agenda
Funding Innovation, Improving LivesResearch and innovation are critical to advancing new therapies for the more than 20 million Americans with kidney disease. Kidney Community Advocacy Day participants will campaign for an additional $150 million per year for 10 years in additional kidney research funding to spur innovation. This funding is needed to help develop new therapies that enhance patients’ lives and ultimately cure this public health burden. Immunosuppressive Coverage—A Common Sense ChoiceKidney transplant recipients must take immunosuppressive drugs to maintain the health of their transplants. Currently, Medicare only covers the cost of these drugs for 36 months. Those who cannot afford to pay for the immunosuppressive drugs (approximately $4,000 per year) end up back on dialysis (the government spends approximately $90,000 a year for care for patients on dialysis).

L-R NephCure Advocate Pam Duquette gives the patient and family perspective as the parent of an FSGS patient, presenting with Nephrologist Sarah Faubel, MD to Congressman Mark Udall’s office

Extending Medicare coverage for immunosuppressive drugs over a recipient’s lifetime is the common sense solution, improving quality of life for people with kidney disease and saving taxpayer dollars.Leaders who participated in Kidney Community Advocacy Day know what’s at stake:

More than 20 million Americans have kidney disease, the 8th leading cause of death in the United States.
200,000 of these Americans are children and adolescents, 15,000 of whom are reliant on dialysis or a kidney transplant to remain alive.
More than 600,000 Americans have kidney failure, known as end-stage renal disease (ESRD).
More than 185,000 Americans live with a kidney transplant and more than 100,000 more are on the wait list.
Nearly all patients with kidney failure are Medicare beneficiaries regardless of age, income, or disability.
ESRD patients account for nearly 7% of Medicare costs but less than 1% of Medicare patients— a total of nearly $35 billion annually.
Nearly 28% of Medicare expenditures involve patients diagnosed with kidney disease.

Share this

NephCure Kidney International Announces NKN Steering Committee Co-Chairs

We are pleased to share that Kathleen Broderick and Randall Snyder were recommended and have accepted their nominations as Steering Committee Co-Chairs for the NephCure Kidney Network (NKN). Kathleen was considered a strong candidate due to her dual experience as a patient caregiver as well as a patient advocacy representative. Similarly, Randy’s dual perspective as a patient caregiver and clinical provider give him unique insight relevant to the NKN.

Kathleen is a member of the NephCure Board of Directors and Research Committee and an editor at DeGruyter Publishing, a Science, Technology, and Medicine (STM) publisher of professional books and scholarly journals in Boston, Massachusetts. Additionally, Kathleen cares for her 16-year-old son, who was diagnosed with Nephrotic Syndrome at 20 months.

Randy is an interventional radiologist with his master’s in molecular biology living in Medford, New Jersey, who cares for his son who was diagnosed with focal segmental glomerulosclerosis.

Kathleen and Randy will be facilitating Steering Committee calls and communication moving forward. Please join us in welcoming Kathleen and Randy as the inaugural NKN Steering Committee Co-Chairs!

Share this

NEW!! Clinical Studies Map!

NephCure Kidney International Introduces Clinical Research Map

October 14, 2014

We are excited to introduce a new user-friendly, interactive clinical research map. This map includes current clinical research sites and studies available to patients affected by FSGS and other Nephrotic Syndrome diseases. The map, which can be found here, will help patients sort through studies available to them. Categories include studies specific to adults, pediatrics, Nephrotic Syndrome, and FSGS, to name a few.

“Patient participation is key to advancing research and treatment options available to patients,” says Marilyn Hailperin, the National Director of Research at NephCure. “This site map allows patients to view studies underway in their area.”

This map is another way NephCure is living out our mission to support research seeking the causes of Nephrotic Syndrome diseases, to improve current treatments and, ultimately, to find a cure. Here at NephCure, we value the supportive role we play for our patients. Spreading the word about clinical research to our patients is a crucial aspect of this role, because, after all, patients power research!

Link to the map: here.

For more information about the risks and benefits of participating in clinical research, click here.

Share this

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Click to Watch…

We’ve said “hello” and “goodbye” to another Countdown to a Cure…

We can’t do this alone.We need you, we’re grateful for you and we thank you.

NephCure Kidney International Introduces Clinical Research Map

Our Mission

Find Us On

We can’t do this alone.
We need you, we’re grateful for you and we thank you.